Mandimycin, which targets a different essential fungi cell resource than other antifungal drugs, should harm other cell types as collateral — but doesn’t.

The team's efforts paid off because the proof-of-concept demonstrated a 95% success rate when they cloned 105 BGCs from 11 Streptomyces strains. Further, they identified five promising BGCs ...